Table 1.
Baseline demographics and clinical characteristics of study participants in LITRA, EMPOWER and PRO-ACT
| Demographic | LITRA (n=50) | EMPOWER | PRO ACT (n=255) | |
| μmol/L (n=449) | mg/dL (n=487) | |||
| Age, years | 56 (11) | 57 (12) | 57 (11) | 57 (11) |
| Male | 33 (66%) | 285 (63%) | 316 (65%) | 159 (62%) |
| Site of symptom onset (bulbar) | 13 (26%) | 103 (23%) | 116 (24%) | 58 (23%) |
| Disease duration from symptom onset, months | 15 (8) | 15 (5) | 15 (5) | 15 (6) |
| FVC (% predicted) | 99 (17) | 90 (17) | 88 (18) | 92 (17) |
| ALSFRS-R | 40 (5) | 39 (5) | 37 (6) | 39 (5) |
| ΔFRS, months* | −0.57 (1.6) | −0.56 (1.6) | −0.68 (1.6) | −0.60 (1.6) |
| Plasma creatinine level (μmol/L) | 74 (14) | 69 (15) | 72 (17) | 68 (15) |
| Male | 79 (13) | 74 (15) | 77 (16) | 73 (15) |
| Female | 64 (11) | 60 (11) | 61 (13) | 61 (13) |
| Bulbar onset | 74 (9) | 71 (14) | 74 (16) | 69 (13) |
| Spinal onset | 74 (15) | 69 (16) | 71 (17) | 68 (16) |
| Number of follow-up measurements | 5 (2) | 11 (3) | 10 (3) | 13 (5) |
Data are mean (SD) or n (%).
*ΔFRS = (ALSFRS-R score at inclusion – 48)/disease duration from symptom onset.
ALSFRS-R, amyotrophic lateral sclerosis functional rating scale–revised; FVC%, forced vital capacity.